Anixa Biosciences Inc.

  Notice of Allowance marks first Korean patent covering Anixa’s breast cancer vaccine platform   Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger breast cancer patients   SAN JOSE, Calif., March 9, 2026 -- Anixa Biosciences, Inc. (“Anixa” or the...

  Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data   SAN JOSE, Calif., March 2, 2026 – Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

  Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higher   Trial expansion reflects growing confidence in intra-peritoneal CAR-T delivery and introduces lymphodepletion to potentially enhance efficacy   Anixa to participate in Water Tower Research fireside chat...

  SAN JOSE, Calif., February 2, 2026 – Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Adopted Names (USAN) Council approved “liraltagene autoleucel” for the non-proprietary name of the Company’s novel FSHR-targeted...

  Notice of Allowance marks first Mexican patent to be issued on Anixa Breast Cancer Vaccine   Expands global intellectual property coverage in markets with greater late-stage breast cancer diagnoses and higher triple-negative breast cancer incidence rates   SAN JOSE, Calif., January 27, 2026 -- Anixa Biosciences, Inc. (“Anixa” or...

  SAN JOSE, Calif., December 15, 2025 -- Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed the transfer of the Investigational New Drug application (“IND”) for its breast cancer vaccine from Cleveland...

  Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose   Results Support Advancement of the Program into Phase 2 Development   Combination of Keytruda® and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 neoadjuvant combination study...

  SAN JOSE, Calif., December 10, 2025 – Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming Water Tower Research Fireside Chat Series taking...

  Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization   SAN JOSE, Calif., November 17, 2025 -- Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the...